{"nctId":"NCT01164722","briefTitle":"Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia","startDateStruct":{"date":"2011-04"},"conditions":["Anal Cancer","Neoplasm of Uncertain Malignant Potential","Nonneoplastic Condition","Precancerous Condition"],"count":120,"armGroups":[{"label":"Arm I: Infrared coagulator treatment","type":"EXPERIMENTAL","interventionNames":["Device: infrared photocoagulation therapy"]},{"label":"Arm II: Expectant management","type":"ACTIVE_COMPARATOR","interventionNames":["Other: clinical observation"]}],"interventions":[{"name":"clinical observation","otherNames":[]},{"name":"infrared photocoagulation therapy","otherNames":["Redfield Infrared Coagulator","Redfield IRC"]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Diagnosis of high-grade anal intraepithelial neoplasia (AIN) meeting the following:\n\n  * AIN2 and/or AIN3 confirmed by biopsy ≥ 2 weeks to ≤ 60 days before enrollment\n  * 1-3 lesions with each lesion ≤ 15 mm in diameter\n  * At least one high-grade AIN lesion is still visible at study entry\n* HIV-infection documented by federally approved, licensed HIV-test in conjunction with screening test (e.g., ELISA, western blot, or other test)\n\n  * HIV-infection, based on prior ELISA and western blot assays, recorded and documented by another physician, allowed provided patient undergoes an approved antibody test to confirm diagnosis\n  * Patients on concurrent anti-retroviral therapy with a history of HIV-positivity based on an approved antibody test allowed\n  * Detectable plasma HIV-1 RNA also allowed\n* No perianal AIN, perianal condyloma, or lower vulvar intraepithelial neoplasia or condyloma requiring treatment\n\nPATIENT CHARACTERISTICS:\n\n* Karnofsky performance status 70-100%\n* Life expectancy ≥ 2 years\n* CD4 count ≥ 200/mm³\n* ANC \\> 750/mm³\n* Platelet count ≥ 75,000/mm³\n* Hemoglobin ≥ 9.0 g/dL\n* INR and aPTT normal\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* Female patients must have undergone cervical pap smear (if having a cervix) and gynecologic evaluation within the past 12 months\n* Must be capable of complying with the requirements of this protocol\n* Concurrent HPV-related disease allowed\n* No history of anal cancer\n* No acute infection or other serious medical illness requiring treatment within the past 14 days\n\n  * Fungal infection of the skin or a sexually transmitted disease requiring treatment allowed\n* No concurrent malignancy requiring systemic therapy\n\n  * Kaposi sarcoma limited to the skin allowed\n\nPRIOR CONCURRENT THERAPY:\n\n* No prior infrared coagulator (IRC) ablation for high-grade anal intraepithelial neoplasia (HGAIN)\n\n  * Prior HGAIN treated by any means other than IRC within the past 2 months allowed\n* At least 5 days since prior coumadin or clopidogrel and ≥ 7 days after study therapy before receiving coumadin or clopidogrel again\n* No concurrent anticoagulant therapy other than aspirin or NSAIDs\n* More than 3 months since prior and concurrent systemic corticosteroids, cytokines, or immunomodulatory therapy (e.g., interferons) or local imiquimod\n* No concurrent systemic therapy","healthyVolunteers":false,"sex":"ALL","minimumAge":"27 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Complete Response Through 1 Year","description":"No detection of high grade anal intraepithelial neoplasia (HGAIN) from treatment through one year. Detection of HGAIN was based on local pathology reports.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]}]},{"type":"SECONDARY","title":"Tolerability and Safety of Infrared Coagulator Ablation","description":"Number of patients who experienced a serious adverse events","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients With High-grade Anal Intraepithelial Neoplasia at 1 Year","description":"Number of patients who had high grade anal intraepithelial neoplasia at one year.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]}]},{"type":"SECONDARY","title":"Recurrence Rate at 1 Year","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Metachronous Lesions","description":"Number of patients with one or more metachronous lesions","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":60},"commonTop":["Anal pain","Postoperative hemorrhage","Anal ulcer","Anal hemorrhage","Diarrhea"]}}}